Gabriel Byrne

Gabriel Byrne

Auto-generated profile, based on publicly available information

Gabriel Byrne

Department of Biomolecular Engineering, University of California Santa Cruz, Santa Cruz, California, United States of America

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 August 2018 in PLOS Biology
Verified
Journal Article
Open access
PDF file
GBGabriel Byrne
Gabriel Byrne
SOSara M O'Rourke
Sara M O'Rourke
DADavid L Alexander
David L Alexander
BYBin Yu
Bin Yu
RDRachel C Doran
Rachel C Doran
PBPhillip W Berman
Phillip W Berman
Over the last decade, multiple broadly neutralizing monoclonal antibodies (bN-mAbs) to the HIV-1 envelope protein (Env) gp120 have been described. Many of these recognize epitopes consisting of both amino acid and glycan residues. Moreover, the glycans required for binding of these bN-mAbs are early intermediates in the N-linked glycosylation pathway. This type of glycosylation substantially alters the mass and net charge of Envs compared to molecules with the same amino acid sequence but possessing mature, complex (sialic acid–containing) carbohydrates. Since cell lines suitable for biopharmaceutical production that limit N-linked glycosylation to mannose-5 (Man5) or earlier intermediates are not readily available, the production of vaccine immunogens displaying these glycan-dependent epitopes has been challenging. Here, we report the development of a stable suspension-adapted Chinese hamster ovary (CHO) cell line that limits glycosylation to Man5 and earlier intermediates. This cell line was created using the clustered regularly interspaced short palindromic repeat (CRISPR)/CRISPR-associated protein 9 (Cas9) gene editing system and contains a mutation that inactivates the gene encoding Mannosyl (Alpha-1,3-)-Glycoprotein Beta-1,2-N-Acetylglucosaminyltransferase (MGAT1). Monomeric gp120s produced in the MGAT1− CHO cell line exhibit improved binding to prototypic glycan-dependent bN-mAbs directed to the V1/V2 domain (e.g., PG9) and the V3 stem (e.g., PGT128 and 10–1074) while preserving the structure of the important glycan-independent epitopes (e.g., VRC01). The ability of the MGAT1− CHO cell line to limit glycosylation to early intermediates in the N-linked glycosylation pathway without impairing the doubling time or ability to grow at high cell densities suggests that it will be a useful substrate for the biopharmaceutical production of HIV-1 vaccine immunogens. Though there is no HIV-1 vaccine available yet, significant progress has been made in understanding the envelope protein structure and the antibodies that bind to it. While most secreted or cell surface eukaryotic proteins contain several large, complex sugar groups, the HIV-1 envelope protein is covered in dense groups of polysaccharides. These sugars are of an intermediate, “high-mannose” form not typically found on eukaryotic proteins. A number of potent antibodies against HIV-1 have been discovered that specifically require these intermediate sugars to bind. This presents a challenge for vaccine production, as the cells used to produce most biopharmaceutical proteins, including previous HIV-1 vaccine candidates, have been selected to incorporate fully processed sugar groups, beyond the intermediate form found on the envelope protein. To address this problem, we used the clustered regularly interspaced palindromic repeat (CRISPR)/CRISPR-associated protein 9 (Cas9) gene editing system to create a Chinese hamster ovary (CHO) cell line that limits the sugar processing to the intermediate, high-mannose form. This paper describes the gene editing process, cell line selection, and antibody binding to the HIV-1 envelope produced. This line is capable of producing envelope proteins that bind the sugar-dependent antibodies, while possessing acceptable growth and production volume characteristics for large-scale manufacturing.

2 August 2018 in PLOS ONE
Verified
Journal Article
Open access
PDF file
SOSara marie Orourke
Sara marie Orourke
GBGabriel Byrne
Gabriel Byrne
GTGwen Tatsuno
Gwen Tatsuno
MWMeredith Wright
Meredith Wright
BYBin Yu
Bin Yu
PBPhillip W Berman
Phillip W Berman
The production of envelope glycoproteins (Envs) for use as HIV vaccines is challenging. The yield of Envs expressed in stable Chinese Hamster Ovary (CHO) cell lines is typically 10–100 fold lower than other glycoproteins of pharmaceutical interest. Moreover, Envs produced in CHO cells are typically enriched for sialic acid containing glycans compared to virus associated Envs that possess mainly high-mannose carbohydrates. This difference alters the net charge and biophysical properties of Envs and impacts their antigenic structure. Here we employ a novel robotic cell line selection strategy to address the problems of low expression. Additionally, we employed a novel gene-edited CHO cell line (MGAT1- CHO) to address the problems of high sialic acid content, and poor antigenic structure. We demonstrate that stable cell lines expressing high levels of gp120, potentially suitable for biopharmaceutical production can be created using the MGAT1- CHO cell line. Finally, we describe a MGAT1- CHO cell line expressing A244-rgp120 that exhibits improved binding of three major families of bN-mAbs compared to Envs produced in normal CHO cells. The new strategy described has the potential to eliminate the bottleneck in HIV vaccine development that has limited the field for more than 25 years.

13 July 2018 in bioRxiv
Verified
Preprint
Open access
PDF file
GBGabriel Byrne
Gabriel Byrne
SOSara M. O’rourke
Sara M. O’rourke
DADavid L. Alexander
David L. Alexander
BYBin Yu
Bin Yu
RDRachel C. Doran
Rachel C. Doran
PBPhillip W. Berman
Phillip W. Berman
Over the last decade multiple broadly neutralizing monoclonal antibodies (bN-mAbs) to the HIV-1 envelope protein, gp120, have been described. Surprisingly many of these recognize epitopes consisting of both amino acid and glycan residues. Moreover, the glycans required for binding of these bN-mAbs are early intermediates in the N-linked glycosylation pathway. This type of glycosylation substantially alters the mass and net charge of HIV envelope (Env) proteins compared to molecules with the same amino acid sequence but possessing mature, complex (sialic acid containing) carbohydrates. Since cell lines suitable for biopharmaceutical production that limit N-linked glycosylation to mannose-5 (Man 5 ) or earlier intermediates are not readily available, the production of vaccine immunogens displaying these glycan dependent epitopes has been challenging. Here we report the development of a stable suspension adapted CHO cell line that limits glycosylation to Man 5 and earlier intermediates. This cell line was created using the CRISPR/Cas9 gene editing system and contains a mutation that inactivates the gene encoding Mannosyl (Alpha-1,3-)-Glycoprotein Beta-1,2-N-Acetylglucosaminyltransferase (MGAT1). Monomeric gp120s produced in the MGAT1 - CHO cell line exhibit improved binding to prototypic glycan dependent bN-mAbs directed to the V1/V2 domain (e.g. PG9) and the V3 stem (e.g. PGT128 and 10–1074) while preserving the structure of the important glycan independent epitopes (e.g. VRC01). The ability of the MGAT1-CHO cell line to limit glycosylation to early intermediates in the N-linked glycosylation pathway, without impairing the doubling time or ability to grow at high cell densities, suggest that it will be a useful substrate for the biopharmaceutical production of HIV-1 vaccine immunogens.

8 May 2018 in bioRxiv
Verified
Preprint
Open access
PDF file
SOSara M. O'Rourke
Sara M. O'Rourke
GBGabriel Byrne
Gabriel Byrne
GTGwen Tatsuno
Gwen Tatsuno
MWMeredith Wright
Meredith Wright
BYBin Yu
Bin Yu
PBPhillip W Berman
Phillip W Berman
The production of envelope glycoproteins (Envs) for use as HIV vaccines is challenging. The yield of Envs expressed in stable Chinese Hamster Ovary (CHO) cell lines is typically 10-100 fold lower than other glycoproteins of pharmaceutical interest. Moreover, Envs produced in CHO cells are typically enriched for sialic acid containing glycans compared to virus associated Envs that possess mainly high-mannose carbohydrates. This difference alters the net charge and biophysical properties of Envs and impacts their antigenic structure. Here we employ a novel gene-edited CHO cell line (MGAT1 - CHO) to address the problems of low expression, high sialic acid content, and poor antigenic structure. We demonstrate that stable cell lines expressing high levels of gp120, potentially suitable for biopharmaceutical production can be created using the MGAT1 - CHO cell line. We also show that the efficiency of this process can be greatly improved with robotic selection. Finally, we describe a MGAT1 - CHO cell line expressing A244-rgp120 that exhibits improved binding of three major families of bN-mAbs compared to Envs produced in normal CHO cells. The new strategy described has the potential to eliminate the bottleneck in HIV vaccine development that has limited the field for more than 25 years.